[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521208":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":35,"centralContacts":39,"locations":44,"responsibleParty":60,"collaborators":27,"id":63,"slug":27,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":27,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":27,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":27,"overallStatus":47,"whyStopped":27,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University of Copenhagen","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Vilanterol + fluticasone furoate","EXPERIMENTAL","Participants are administered Vilanterol + fluticasone furoate from an inhaler device testing",[13,14],"Drug: Vilanterol and Fluticasone Furoate (low dose)","Drug: Vilanterol and Fluticasone Furoate (high dose)",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo","PLACEBO_COMPARATOR","Participants are administered placebo from an inhaler device testing",[20],"Drug: Placebo",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Vilanterol and Fluticasone Furoate (low dose)","Participants are administered 25 µg of vilanterol + fluticasone furoate",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Vilanterol and Fluticasone Furoate (high dose)","Participants are administered 100 µg of vilanterol + fluticasone furoate",[9],{"type":23,"name":16,"description":33,"armGroupLabels":34,"otherNames":27},"Participants are administered placebo",[16],[36],{"name":37,"affiliation":5,"role":38},"Morten Hostrup, PhD","PRINCIPAL_INVESTIGATOR",[40],{"name":37,"role":41,"phone":42,"phoneExt":27,"email":43},"CONTACT","+4535321595","mhostrup@nexs.ku.dk",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"August Krogh Building","RECRUITING","Copenhagen","DK","2100","Denmark",{"type":53,"coordinates":54},"Point",[55,56],12.56553,55.67594,{"lat":56,"lon":55},[59],{"name":37,"role":41,"phone":27,"phoneExt":27,"email":27},{"type":61,"investigatorFullName":37,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"SPONSOR_INVESTIGATOR","Associate Professor","100521208",false,"NCT06066606","U-LABA\u002FICS Effects on Exercise Performance, Vilanterol","Physiological Response to U-LABA\u002FICS With Emphasis on Exercise Performance, Vilanterol","Inclusion Criteria:\n\n* Age 18-39\n* Physically active \\> 5 h weekly\n* Maximal oxygen consumption classified as high or very high\n\nExclusion Criteria:\n\n* Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist\u002Fcorticosteroid\n* ECG abnormality\n* ACQ score \\> 1.5\n* Severe bronchial hyperreactivity as determined by mannitol test\n* FEV1\u002FFVC ratio \\\u003C 0.7 determined with spirometry\n* Chronic illness determined to be a potential risk for participant during study\n* In chronic treatment with medication that may interfere with study results\n* Pregnancy\n* Smoker\n* Blood donation during the past 3 months",true,"ALL","18 Years","39 Years",{"count":74,"type":75},30,"ESTIMATED","INTERVENTIONAL",[78],"NA","The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate",[81],"Exercise Performance","2025-04-07",{"date":84,"type":85},"2025-04-10","ACTUAL",{"date":87,"type":85},"2023-10-03",{"date":89,"type":75},"2026-12-01",{"name":37,"class":6},1]